Malvinder Mohan Singh: Difference between revisions

Malvinder Mohan Singh is one of the sons of Dr. Parvinder Singh and the grandson of Bhai Mohan Singh, the founder of Ranbaxy.<ref>{{cite news|title=40 Years Ago... And now: Ranbaxy grew with liberal regimes, moving out of family control|url=http://www.business-standard.com/article/companies/40-years-ago-and-now-ranbaxy-grew-with-liberal-regimes-moving-out-of-family-control-114102101500_1.html|newspaper=Business Standard India|accessdate=16 December 2014|date=22 October 2014|last1=Bhandari|first1=Bhupesh}}</ref> He and his brother [[Shivinder Mohan Singh|Shivinder Singh]] inherited their father's 33.5% stake in Ranbaxy upon his death in 1999. The two used to be among the twenty richest people in India.<ref>[https://archive.today/20120730143533/http://www.forbes.com/finance/lists/77/2004/LIR.jhtml?passListId=77&passYear=2004&passListType=Person&uniqueId=DN7N&datatype=Person Forbes.com: India's Richest 2004]</ref>

Singh attended [[The Doon School]], [[Dehradun]],<ref>{{cite web|url=http://www.outlookindia.com/article.aspx?230938 |title=Class Up at Doon &#124; Anjali Puri |publisher=Outlookindia.com |date= |accessdate=6 April 2013}}</ref> and graduated with a degree in economics from [[St. Stephen's College, Delhi]]. He also received a masters of business administration (MBA) from [[Duke University]]'s [[Fuqua School of Business]].<ref>https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ranbaxy-to-ruins-how-the-singh-brothers-turned-from-business-whizkids-to-fraud-accused/articleshow/67176061.cms?from=mdr</ref>

Malvinder Singh's tenure as CEO of Ranbaxy is controversial. A corporate culture of fraud prevailed under his leadership. In November 2006, Singh led a delegation to FDA headquarters to try to reverse the decision not to accept new drug applications from Ranbaxy. This attempt failed as the FDA asked Ranbaxy to turn over audits done by its outside consultant, Parexel, which the company was claiming were confidential. The meeting ended in a standoff. On 11 June 2008, Singh stunned the Indian business world by announcing that he and his brother were selling their 33.5% stake in Ranbaxy to the Japanese drugmaker Daiichi Sankyo for $2 billion.{{citation needed|date=May 2020}}

Malvinder Singh is the founder of Religare Wellness (now [[Fortis Healthcare]]).<ref>https://www.forbes.com/profile/malvinder-shivinder-singh/ Forbes Profile of Malvinder and Shivinder Singh</ref>